Jimmy Van den Eynden

MD, PhD, PI@CCGG, prof@GhentUniversity

[Jimmy Van den Eynden @JimmyVdE]

We're recruiting a PhD student to perform research on the fascinating crossroads between engineering and cancer genomics.
Joint PhD project with @jvdesomp
@crighent @UGent_HSR @ugent_fge
https://t.co/SFTYBBSTj2

[Jimmy Van den Eynden @JimmyVdE]

@elonmuskADO 35 🤷🏻‍♂️

[Jimmy Van den Eynden @JimmyVdE]

Congratulations to Sofie Hoogstoel for winning the best poster prize at the NAV 2024 anatomy conference in Lunteren. Her poster demonstrated the potential of whole-body donors in studying early carcinogenesis.

[Jimmy Van den Eynden @JimmyVdE]

Honored to have hosted @RuthPalmerALK and @bengtHallberg for 2 interesting @crighent seminars last week @ugent_fge. Many fruitful scientific discussions with @SpelemanLab. Very excited about this new collaboration and convinced we will make a difference in #neuroblastoma research

[Dr Kerryn Elliott 🇦🇺🇸🇪 @Kerryn_Elliott]

Happy to share our latest study, where we use UV light to map protein-DNA interactions using a capture based CPD-seq method. This represents a massive enrichment in CPDs over previous genome-wide studies
https://t.co/vhMthCntoh

[Jimmy Van den Eynden @JimmyVdE]

Particularly liked how they demonstrate monoallelic loss of the HLA allele with the best neoantigen presenting capacity!

[Jimmy Van den Eynden @JimmyVdE]

Genetic immune escape is present in minimally 25% of tumors and this prevalence is remarkably similar between primary and metastatic tumors. I wrote @NatureGenet News and Views article on this nice work from @fran_mj88 and colleagues from the Cuppen lab.
https://t.co/hWb7YZAew0

[Jimmy Van den Eynden @JimmyVdE]

@fran_mj88 @Nature @NatureGenetics Congrats! I wrote a News & Views article about your work. https://t.co/wZBJqRmIxZ Particularly liked how you demonstrate monoallelic loss of the HLA allele with the best neoantigen presenting capacity!

[Jimmy Van den Eynden @JimmyVdE]

Based on an extensive benchmarking effort we recommend Optitype and HLA-HD for MHC class I and class II genotyping from NGS data, respectively.
https://t.co/wRS9ANamPe

[Jimmy Van den Eynden @JimmyVdE]

Congratulations to @JoachimSiaw for receiving the @crighent Young Investigator Proof-Of-Concept project funding. The funding will allow him to evaluate the therapeutic efficacy of RUVBL inhibitors in #Neuroblastoma mice models. https://t.co/BUiPBeHSaA

[Jimmy Van den Eynden @JimmyVdE]

@CR_AACR @xsliu9 @WangShxiang As we have demonstrated in a https://t.co/2W7eL3ddru, we believe this is another illustration of the misinterpretation of HLA affinity signals in cancer genomics.

[Jimmy Van den Eynden @JimmyVdE]

4.Citing your own unpublished preprints as scientific facts is a very questionable scientific practice!

[Jimmy Van den Eynden @JimmyVdE]

In a Letter to The Editor of @CR_AACR we demonstrate that the immunoediting signals perceived by Wu et al in https://t.co/NFeZzmbxqd are false. https://t.co/2W7eL3ddru
Another illustration of the misinterpretation of HLA affinity signals in cancer genomics!

Our main concerns:

[Jimmy Van den Eynden @JimmyVdE]

https://t.co/H8rlSHMWdZïve data filtering = asking for problems. When only 10% of mutations are neoantigenic, removing samples without these mutations is problematic in tumors with low TMB.

[Jimmy Van den Eynden @JimmyVdE]

ALK fusion oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression. Congratulations to Tzu-Po Chuang, Jonatan Gabre, Bengt Hallberg and colleagues with the publication of this important work in PNAS today https://t.co/Vuw9tl7zj8

[Jimmy Van den Eynden @JimmyVdE]

Excited to formally kickoff the European #PerImmune project with @WimCeelen and colleagues!

[Wim Ceelen @WimCeelen]

Kickoff of the @TRANSCAN Perimmune project! Our aim is to unravel the immune TME of colorectal PM and develop novel IP therapies @flatmark_k

[Charlotte Scott @KC_DC_01]

Together with @fspelema & @goossens_lab we are looking for a motivated postdoc to study the tumour-immune microenvironment in neuroblastoma at @ugent & @VIBLifeSciences Deadline for applications is 28th Feb. Apply here: https://t.co/FWu1MAYw5v

[Jimmy Van den Eynden @JimmyVdE]

In addition to the funding @joachimsiaw received from AGFond and @komop_tgkanker and @FWOVlaanderen PhD fellowships from @TomLuijts and Arne Claeys, this has been a very successful year for the lab! https://t.co/K0BtkEAHJq

[Jimmy Van den Eynden @JimmyVdE]

Exciting scientific times at CCGG lab with recently obtained funding from @FWOVlaanderen and @Stkstichting for our #neuroblastoma research (collaboration with @SpelemanLab and Palmer lab) and from @crighent for our research on mutant skin clones (collaboration with @IHoorens).